{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T01:59:18Z","timestamp":1785549558500,"version":"3.56.0"},"reference-count":49,"publisher":"Medical Association of Nippon Medical School","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nippon Med Sch"],"published-print":{"date-parts":[[2024,2,25]]},"DOI":"10.1272\/jnms.jnms.2024_91-104","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T22:13:34Z","timestamp":1701987214000},"page":"48-58","source":"Crossref","is-referenced-by-count":2,"title":["Atypical Clinical Courses of Graves' Disease Confound Differential Diagnosis of Hyperthyroidism"],"prefix":"10.1272","volume":"91","author":[{"given":"Yuji","family":"Yamaguchi","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Metabolism and Nephrology, Graduate School of Medicine, Nippon Medical School"},{"name":"Department of Diabetes, Endocrinology and Metabolism, Nippon Medical School Chiba Hokusoh Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitaka","family":"Okajima","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism and Nephrology, Graduate School of Medicine, Nippon Medical School"},{"name":"Department of Diabetes, Endocrinology and Metabolism, Nippon Medical School Chiba Hokusoh Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Sugihara","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism and Nephrology, Graduate School of Medicine, Nippon Medical School"},{"name":"IVY Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Iwabu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism and Nephrology, Graduate School of Medicine, Nippon Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Emoto","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism and Nephrology, Graduate School of Medicine, Nippon Medical School"},{"name":"Department of Diabetes, Endocrinology and Metabolism, Nippon Medical School Chiba Hokusoh Hospital"},{"name":"Diabetes &amp; Endocrine Clinic, Sakura Chuo Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"21","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Bartalena L. Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol. 2013;9:724-34.","DOI":"10.1038\/nrendo.2013.193"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kahaly GJ, Dillmann WH. Thyroid hormone action in the heart. Endocr Rev. 2005;26:704-28.","DOI":"10.1210\/er.2003-0033"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Biondi B, Kahaly GJ. Cardiovascular involvement in patients with different causes of hyperthyroidism. Nat Rev Endocrinol. 2010;6:431-43.","DOI":"10.1038\/nrendo.2010.105"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Sundaresh V, Brito JP, Wang Z, et al. Comparative effectiveness of therapies for Graves&apos; hyperthyroidism: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2013;98:3671-7.","DOI":"10.1210\/jc.2013-1954"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Otsuka F, Noh JY, Chino T, et al. Hepatotoxicity and cutaneous reactions after antithyroid drug administration. Clin Endocrinol (Oxf). 2012;77:310-5.","DOI":"10.1111\/j.1365-2265.2012.04365.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Watanabe N, Narimatsu H, Noh JY, et al. Antithyroid drug-induced hematopoietic damage: a retrospective cohort study of agranulocytosis and pancytopenia involving 50,385 patients with Graves&apos; disease. J Clin Endocrinol Metab. 2012;97:E49-53.","DOI":"10.1210\/jc.2011-2221"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26:1343-421.","DOI":"10.1089\/thy.2016.0229"},{"key":"8","unstructured":"8. Harper PV, Andros G, Lathrop K. Preliminary observations on the use of six-hour Tc<sup>99m<\/sup> as a tracer in biology and medicine. Argonne Cancer Research Hospital Semiannul Report to the Atomic Energy Commission. Washington, DC: Office of Technical Services, Department of Commerce; 1962. p. 76-88."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Andros G, Harper PV, Lathrop KA. Pertechnetate-99m localization in man with applications to thyroid scanning and the study of thyroid physiology. J Clin Endocrinol Metab. 1965;25:1067-76.","DOI":"10.1210\/jcem-25-8-1067"},{"key":"10","unstructured":"10. Atkins HL, Richards P. Assessment of thyroid function and anatomy with technetium-99m as pertechnetate. J Nucl Med. 1968;9:7-15."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Hoff W van&apos;t, Pover GG, Eiser NM. Technetium-99m in the diagnosis of thyrotoxicosis. Br Med J. 1972;4:203-6.","DOI":"10.1136\/bmj.4.5834.203"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Uchida T, Suzuki R, Kasai T, et al. Cutoff value of thyroid uptake of (99m) Tc-pertechnetate to discriminate between Graves&apos; disease and painless thyroiditis: a single center retrospective study. Endocr J. 2016;63:143-9.","DOI":"10.1507\/endocrj.EJ15-0441"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Zuhur SS, Ozel A, Kuzu I, et al. The diagnostic utility of color doppler ultrasonography, Tc-99m pertechnetate uptake, and TSH-receptor antibody for differential diagnosis of Graves&apos; disease and silent thyroiditis: a comparative study. Endocr Pract. 2014;20:310-9.","DOI":"10.4158\/EP13300.OR"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Scappaticcio L, Trimboli P, Keller F, Imperiali M, Piccardo A, Giovanella L. Diagnostic testing for Graves&apos; or non-Graves&apos; hyperthyroidism: a comparison of two thyrotropin receptor antibody immunoassays with thyroid scintigraphy and ultrasonography. Clin Endocrinol (Oxf). 2020;92:169-78.","DOI":"10.1111\/cen.14130"},{"key":"15","unstructured":"15. Japan Thyroid Association. Guideline for the diagnosis of Graves&apos; disease [Internet]. 2022 Jun 2 [cited 2023 Mar 19]. Available from: https:\/\/www.japanthyroid.jp\/en\/guidelines.html#Gra"},{"key":"#cr-split#-16.1","doi-asserted-by":"crossref","unstructured":"16. Kahaly GJ, Bartalena L, Hegedus L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association guideline for the management of Graves&apos","DOI":"10.1159\/000490384"},{"key":"#cr-split#-16.2","doi-asserted-by":"crossref","unstructured":"hyperthyroidism. Eur Thyroid J. 2018;7:167-86.","DOI":"10.1159\/000490384"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kidokoro-Kunii Y, Emoto N, Cho K, Oikawa S. Analysis of the factors associated with Tc-99m pertechnetate uptake in thyrotoxicosis and graves&apos; disease. J Nippon Med Sch. 2006;73:10-7.","DOI":"10.1272\/jnms.73.10"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kageyama K, Kinoshita N, Daimon M. A case of thyrotoxicosis due to simultaneous occurrence of subacute thyroiditis and Graves&apos; disease. Case Rep Endocrinol. 2018;2018:3210317.","DOI":"10.1155\/2018\/3210317"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Hoang TD, Mai VQ, Clyde PW, Shakir MK. Simultaneous occurrence of subacute thyroiditis and Graves&apos; disease. Thyroid. 2011;21:1397-400.","DOI":"10.1089\/thy.2011.0254"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Ylli D, Wartofsky L, Burman KD. Evaluation and treatment of amiodarone-induced thyroid disorders. J Clin Endocrinol Metab. 2021;106:226-36.","DOI":"10.1210\/clinem\/dgaa686"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Klein I, Danzi S. Thyroid disease and the heart.  Circulation. 2007;116:1725-35.","DOI":"10.1161\/CIRCULATIONAHA.106.678326"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Burch HB, Wartofsky L. Life-threatening thyrotoxicosis. Thyroid storm. Endocrinol Metab Clin North Am. 1993;22:263-77.","DOI":"10.1016\/S0889-8529(18)30165-8"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Hall P, Lundell G, Holm LE. Mortality in patients treated for hyperthyroidism with iodine-131. Acta Endocrinol (Copenh). 1993;128:230-4.","DOI":"10.1530\/acta.0.1280230"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med. 2003;348:2646-55.","DOI":"10.1056\/NEJMra021194"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Jin M, Ahn J, Jo SG, et al. Comparison of <sup>99m<\/sup>Tc pertechnetate thyroid uptake rates by gamma probe and gamma camera methods for differentiating Graves&apos; disease and thyroiditis. Nucl Med Mol Imaging. 2022;56:42-51.","DOI":"10.1007\/s13139-021-00734-2"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Malik SA, Choh NA, Misgar RA, et al. Comparison between peak systolic velocity of the inferior thyroid artery and technetium-99m pertechnetate thyroid uptake in differentiating Graves&apos; disease from thyroiditis. Arch Endocrinol Metab. 2019;63:495-500.","DOI":"10.20945\/2359-3997000000165"},{"key":"27","unstructured":"27. Fadime D. Cut off value of technetium uptake in the differential diagnosis of Graves&apos; disease and subacute thyroiditis. Asia Ocean J Nucl Med Biol. 2020;8:54-7."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Salvatore D, Tu H, Harney JW, Larsen PR. Type 2 iodothyronine deiodinase is highly expressed in human thyroid. J Clin Invest. 1996;98:962-8.","DOI":"10.1172\/JCI118880"},{"key":"29","doi-asserted-by":"publisher","unstructured":"29. Murakami M, Araki O, Hosoi Y, et al. Expression and regulation of type II iodothyronine deiodinase in human thyroid gland. Endocrinology. 2001;142:2961-7.","DOI":"10.1210\/en.142.7.2961"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Shigemasa C, Abe K, Taniguchi S, et al. Lower serum free thyroxine (T4) levels in painless thyroiditis compared with Graves&apos; disease despite similar serum total T4 levels. J Clin Endocrinol Metab. 1987;65:359-63.","DOI":"10.1210\/jcem-65-2-359"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Yanagisawa T, Sato K, Kato Y, Shimizu S, Takano K. Rapid differential diagnosis of Graves&apos; disease and painless thyroiditis using total T3\/T4 ratio, TSH, and total alkaline phosphatase activity. Endocr J. 2005;52:29-36.","DOI":"10.1507\/endocrj.52.29"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Bogazzi F, Vitti P. Could improved ultrasound and power Doppler replace thyroidal radioiodine uptake to assess thyroid disease? Nat Clin Pract Endocrinol Metab. 2008;4:70-1.","DOI":"10.1038\/ncpendmet0692"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Barbesino G, Tomer Y. Clinical review: Clinical utility of TSH receptor antibodies. J Clin Endocrinol Metab. 2013;98:2247-55.","DOI":"10.1210\/jc.2012-4309"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Sayama N, Yoshida K, Mori K, et al. Measurement of red blood cell zinc concentration with Zn-test kit: discrimination between hyperthyroid Graves&apos; disease and transient thyrotoxicosis. Endocr J. 1998;45:767-72.","DOI":"10.1507\/endocrj.45.767"},{"key":"35","unstructured":"35. Yoshimura Noh J, Hamada N, Shimizu T, Ishikawa N, Ito K, Ito K. [Establishment of cut off value and clinical effect by TRAb measurement kit using human recombinant TSH receptor]. Japanese Journal of Medicine and Pharmaceutical Science. 2002;47:127-33. Japanese."},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Carvalho GA, Perez CL, Ward LS. The clinical use of thyroid function tests. Arq Bras Endocrinol Metabol. 2013;57:193-204.","DOI":"10.1590\/S0004-27302013000300005"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Takasu N, Yamashiro K, Ochi Y, et al. TSBAb (TSH-stimulation blocking antibody) and TSAb (thyroid stimulating antibody) in TSBAb-positive patients with hypothyroidism and Graves&apos; patients with hyperthyroidism. Horm Metab Res. 2001;33:232-7.","DOI":"10.1055\/s-2001-14942"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Spencer C, Petrovic I, Fatemi S, LoPresti J. Serum thyroglobulin (Tg) monitoring of patients with differentiated thyroid cancer using sensitive (second-generation) immunometric assays can be disrupted by false-negative and false-positive serum thyroglobulin autoantibody misclassifications. J Clin Endocrinol Metab. 2014;99:4589-99.","DOI":"10.1210\/jc.2014-1203"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Fradkin JE, Wolff J. Iodide-induced thyrotoxicosis. Medicine (Baltimore). 1983;62:1-20.","DOI":"10.1097\/00005792-198301000-00001"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Morita T, Tamai H, Oshima A, et al. The occurrence of thyrotropin binding-inhibiting immunoglobulins and thyroid-stimulating antibodies in patients with silent thyroiditis. J Clin Endocrinol Metab. 1990;71:1051-5.","DOI":"10.1210\/jcem-71-4-1051"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Sanyal D, Chatterjee S. Thyrotropin receptor antibody immunoassays may not be reliable in confirming diagnosis of Painless Thyroiditis. Acta Endocrinol (Buchar). 2020;16:530-4.","DOI":"10.4183\/aeb.2020.530"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Takasu N, Yamada T, Sato A, et al. Graves&apos; disease following hypothyroidism due to Hashimoto&apos;s disease: studies of eight cases. Clin Endocrinol (Oxf). 1990;33:687-98.","DOI":"10.1111\/j.1365-2265.1990.tb03906.x"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Sukik A, Mohamed S, Habib MB, et al. The unusual late-onset Graves&apos; disease following Hashimoto&apos;s related hypothyroidism: a case report and literature review. Case Rep Endocrinol. 2020;2020:5647273.","DOI":"10.1155\/2020\/5647273"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Gonzalez-Aguilera B, Betea D, Lutteri L, et al. Conversion to Graves disease from Hashimoto thyroiditis: a study of 24 patients. Arch Endocrinol Metab. 2018;62:609-14.","DOI":"10.20945\/2359-3997000000086"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. El Sabbagh R, Azar NS, Eid AA, Azar ST. Thyroid dysfunctions due to immune checkpoint inhibitors: a review. Int J Gen Med. 2020;13:1003-9.","DOI":"10.2147\/IJGM.S261433"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Ferrari SM, Fallahi P, Galetta F, Citi E, Benvenga S, Antonelli A. Thyroid disorders induced by checkpoint inhibitors. Rev Endocr Metab Disord. 2018;19:325-33.","DOI":"10.1007\/s11154-018-9463-2"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Kobayashi T, Iwama S, Yasuda Y, et al. Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study. J Endocr Soc. 2018;2:241-51.","DOI":"10.1210\/js.2017-00432"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Yamada H, Okajima F, Onda T, Fujimori S, Emoto N, Sugihara H. New-onset graves&apos; disease after the initiation of nivolumab therapy for gastric cancer: a case report. BMC Endocr Disord. 2020;20:132.","DOI":"10.1186\/s12902-020-00613-5"}],"container-title":["Journal of Nippon Medical School"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/91\/1\/91_JNMS.2024_91-104\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T05:12:50Z","timestamp":1715577170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnms\/91\/1\/91_JNMS.2024_91-104\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,25]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1272\/jnms.jnms.2024_91-104","relation":{},"ISSN":["1345-4676","1347-3409"],"issn-type":[{"value":"1345-4676","type":"print"},{"value":"1347-3409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,25]]},"article-number":"JNMS.2024_91-104"}}